PDCD1 and neoplasm: Immunotherapy based on antibodies that neutralize PD-1 or its ligand PD-L1 effectively restores exhausted T cell-mediated anti-tumor responses in a variety of advanced cancers in humans, with durable effects and high efficacy compared with standard cancer treatments [5].